TM4SF5 and malignant colon neoplasm: Another study demonstrated that combining humanized anti-TM4SF5 mAb and TM4SF5-specific peptide-based vaccine can strengthen their anticancer impact and reduce the metastatic potential of colon cancer in vivo (72).